|
Liver carcinoma
|
0.700 |
Biomarker
|
disease |
HPO |
|
|
|
|
Liver carcinoma
|
0.700 |
CausalMutation
|
disease |
CGI |
|
|
|
|
Liver carcinoma
|
0.700 |
CausalMutation
|
disease |
CLINVAR |
|
|
|
|
Micronodular cirrhosis
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Somatic mutation
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Subacute progressive viral hepatitis
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Turcot syndrome (disorder)
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Mismatch repair deficiency is thought to lead to mutation and inactivation of the genes for type II TGF-beta receptor and insulin-like growth-factor II receptor.
|
9438104 |
1998 |
|
Squamous cell carcinoma
|
0.040 |
GeneticVariation
|
disease |
BEFREE |
Insulin-like growth factor II receptor gene-167 genotype increases the risk of oral squamous cell carcinoma in humans.
|
12543777 |
2003 |
|
Locally Advanced Squamous Cell Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
M6P/IGF2R loss of heterozygosity in locally advanced squamous cell carcinoma of the head and neck was assessed with six different gene-specific nucleotide polymorphisms.
|
12589712 |
2003 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IGF2R, with multiple functions in both normal growth and cancer, was investigated here as a possible USF target in both nontumorigenic and tumorigenic breast cell lines.
|
12857727 |
2003 |
|
Primary malignant neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
IGF2R, with multiple functions in both normal growth and cancer, was investigated here as a possible USF target in both nontumorigenic and tumorigenic breast cell lines.
|
12857727 |
2003 |
|
Malignant neoplasm of breast
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
IGF2R promoter-driven expression was USF-independent in both MCF-7 and MDA-MB-231 breast cancer cell lines, suggesting that a defect in USF function may contribute to down-regulation of IGF2R expression in cancer cells.
|
12857727 |
2003 |
|
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
IGF2R promoter-driven expression was USF-independent in both MCF-7 and MDA-MB-231 breast cancer cell lines, suggesting that a defect in USF function may contribute to down-regulation of IGF2R expression in cancer cells.
|
12857727 |
2003 |
|
Kaposi Sarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Insulin-like growth factor II receptor-mediated intracellular retention of cathepsin B is essential for transformation of endothelial cells by Kaposi's sarcoma-associated herpesvirus.
|
17507477 |
2007 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
M6P/IGF2R was found to be polymorphic in 73.3% (22/30) of the patients, and of these patients, 50.0% (11/22) had tumors showing LOH in M6P/IGF2R.
|
18322954 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IGF2R has been proposed to be a tumor suppressor gene given its antagonist role on cellular growth and evidence of loss of heterozygosity in several cancers, including breast cancer.
|
19435860 |
2009 |
|
Delirium, Dementia, Amnestic, Cognitive Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Insulin-like growth factor 2 receptor is an IFNgamma-inducible microglial protein that facilitates intracellular HIV replication: implications for HIV-induced neurocognitive disorders.
|
20889566 |
2010 |
|
Neurocognitive Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Insulin-like growth factor 2 receptor is an IFNgamma-inducible microglial protein that facilitates intracellular HIV replication: implications for HIV-induced neurocognitive disorders.
|
20889566 |
2010 |
|
Neoplasm Metastasis
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
IGF2R genetic polymorphism may be associated with decreased function of IGF2 receptor there by contributing to the advancement and distant metastasis of localized oral cancer.
|
21347719 |
2012 |
|
Malignant neoplasm of mouth
|
0.020 |
GeneticVariation
|
group |
BEFREE |
IGF2R genetic polymorphism may be associated with decreased function of IGF2 receptor there by contributing to the advancement and distant metastasis of localized oral cancer.
|
21347719 |
2012 |
|
Lip and Oral Cavity Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
IGF2R genetic polymorphism may be associated with decreased function of IGF2 receptor there by contributing to the advancement and distant metastasis of localized oral cancer.
|
21347719 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
IGF2R was overexpressed significantly more frequently in HR negative tumors (p = 0.001) and had an inverse correlation with all other biomarkers.
|
24637962 |
2014 |
|
Tumor Cell Invasion
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
IGF2R inhibition by si-RNA technique in NSCLC cell lines increased the proliferation, migration and invasion abilities, but reduced the apoptosis rate.
|
25402559 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
M6P/IGF2R is a multifunctional receptor involved in protein sorting, internalization, and degradation, being considered a tumor suppressor.
|
29318541 |
2018 |
|
Fetal Growth Retardation
|
0.240 |
Biomarker
|
phenotype |
BEFREE |
IGF2R expression was significantly decreased in placentas from pregnancies complicated by idiopathic FGR (P < 0.05 versus control). siRNA-mediated IGF2R knockdown in term placental explants and the trophoblast cell line BeWo resulted in altered expression of homeobox gene transcription factors, including increased expression of distal-less homeobox gene 5 (DLX5), and decreased expression of H2.0-Like Homeobox 1 (HLX) (P < 0.05 versus control).
|
31418778 |
2019 |